Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Cencora, Inc. (symbol: COR) has filed a Form 144 with the U.S. Securities and Exchange Commission, indicating a proposed insider sale of common stock under Rule 144.
The notice covers the potential disposition of 1,000 common shares through broker Goldman Sachs & Co. LLC. The sale is tentatively scheduled for 18 June 2025 on the NYSE. At a stated aggregate market value of $293,200, the implied reference price is roughly $293.20 per share.
The filing shows the shares were originally granted to the seller as restricted stock awards on two dates—20 Aug 2013 (500 shares) and 09 Aug 2016 (500 shares)—as part of compensation from Cencora. No prior sales have been reported in the past three months, and the person filing affirms no knowledge of undisclosed material adverse information about the company.
Relative to the total outstanding share count of 193,823,487, the proposed sale represents approximately 0.0005 % of shares outstanding, suggesting minimal dilution or market impact. The filing is routine in nature, providing transparency around a small insider transaction rather than signaling any broader strategic change.